Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMNM Immunome	$8.79 +1.3%	$8.59	$5.15 ▼ $16.81	$755.27M	1.94	900,176 shs	628,148 shs
KYMR Kymera Therapeutics	$45.71 -1.6%	$36.72	$19.45 ▼ $53.27	$3.03B	2.07	614,580 shs	1.42 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
VKTX Viking Therapeutics	$28.17 +4.0%	$27.14	$18.92 ▼ $81.73	$3.04B	0.65	4.05 million shs	5.36 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMNM Immunome	+1.27%	-0.45%	+2.21%	+25.75%	-26.93%
KYMR Kymera Therapeutics	-1.64%	-1.57%	+62.44%	+54.32%	+52.93%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	+5.63%
VKTX Viking Therapeutics	+3.99%	+7.19%	+3.64%	+9.82%	-40.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMNM Immunome	1.6139 of 5 stars	3.5	0.0	0.0	0.0	2.2	2.5	0.0
KYMR Kymera Therapeutics	3.3439 of 5 stars	4.5	3.0	0.0	0.0	3.1	1.7	0.0
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	4.4359 of 5 stars	4.5	1.0	0.0	4.7	2.1	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMNM Immunome	3.00	Buy	$23.33	165.45% Upside
KYMR Kymera Therapeutics	3.00	Buy	$59.78	30.78% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
VKTX Viking Therapeutics	3.00	Buy	$87.15	209.39% Upside

Current Analyst Ratings Breakdown

Latest IMNM, KYMR, VKTX, and MOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00
6/25/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
6/3/2025	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
6/3/2025	KYMR Kymera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $64.00
6/3/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$38.00 ➝ $60.00
6/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$49.00 ➝ $79.00
6/2/2025	KYMR Kymera Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$51.00
5/20/2025	KYMR Kymera Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$55.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMNM Immunome	$9.04M	84.60	N/A	N/A	$2.27 per share	3.87
KYMR Kymera Therapeutics	$47.07M	63.24	N/A	N/A	$12.90 per share	3.54
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMNM Immunome	-$292.96M	-$3.18	N/A	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)

Latest IMNM, KYMR, VKTX, and MOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMNM Immunome	N/A	10.49	10.49
KYMR Kymera Therapeutics	N/A	8.49	8.49
MOR MorphoSys	4.98	1.38	1.38
VKTX Viking Therapeutics	N/A	44.25	44.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMNM Immunome	44.58%
KYMR Kymera Therapeutics	N/A
MOR MorphoSys	18.38%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
IMNM Immunome	8.60%
KYMR Kymera Therapeutics	16.01%
MOR MorphoSys	0.05%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMNM Immunome	40	87.01 million	79.53 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable

IMNM, KYMR, VKTX, and MOR Headlines

Recent News About These Companies

HC Wainwright Reiterates "Buy" Rating for Viking Therapeutics (NASDAQ:VKTX)

3 hours ago | americanbankingnews.com

Why This Weight Loss Drug Company's Stock Surged Today

June 26 at 3:06 PM | fool.com

VKTX Initiates Phase 3 Study on Obesity Candidate VK2735

June 26 at 12:16 PM | zacks.com

VKTX Viking Therapeutics, Inc. - Seeking Alpha

June 26 at 10:08 AM | seekingalpha.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Stock Holdings Increased by International Assets Investment Management LLC

June 26 at 4:46 AM | marketbeat.com

Oppenheimer & Co. Inc. Acquires 23,481 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 26 at 4:17 AM | marketbeat.com

Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity

June 25 at 2:26 PM | msn.com

Viking Therapeutics (NASDAQ:VKTX) Receives "Buy" Rating from HC Wainwright

June 25 at 11:11 AM | marketbeat.com

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

June 25 at 7:03 AM | prnewswire.com

My 5 Favorite Dirt Cheap Stocks to Buy Right Now

June 24 at 7:10 AM | fool.com

Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.8% - Here's Why

June 23, 2025 | marketbeat.com

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

June 21, 2025 | fool.com

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

June 20, 2025 | msn.com

Institute for Wealth Management LLC. Purchases 9,735 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 19, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by GAMMA Investing LLC

June 19, 2025 | marketbeat.com

MN Wealth Advisors LLC Has $450,000 Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 18, 2025 | marketbeat.com

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

June 16, 2025 | zacks.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Handelsbanken Fonder AB

June 16, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.7% - Should You Sell?

June 13, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Holdings Lifted by Compagnie Lombard Odier SCmA

June 13, 2025 | marketbeat.com

Viking Therapeutics (VKTX) Rises on Expected Developments

June 12, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks

IMNM, KYMR, VKTX, and MOR Company Descriptions

Immunome NASDAQ:IMNM

$8.79 +0.11 (+1.27%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$8.79 0.00 (0.00%)

As of 06/26/2025 04:23 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Kymera Therapeutics NASDAQ:KYMR

$45.71 -0.76 (-1.64%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$45.62 -0.09 (-0.21%)

As of 04:00 AM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 06/25/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Viking Therapeutics NASDAQ:VKTX

$28.17 +1.08 (+3.99%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$28.55 +0.38 (+1.35%)

As of 04:58 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time